The study seeks to provide long-term follow-up and/or to offer continued maintenance thalidomide (THALOMID) therapy to those patients enrolled in 20030165. Patients will be followed until withdrawal of consent, or death.
Inclusion Criteria: 1. Enrolled on the 20030165 clinical trial. 2. Ability to understand and willingness to sign a written informed consent document. Exclusion Criteria: 1. Patients who were discontinued from 20030165 for any reason prior to the completion of protocol-specified treatment (e.g. withdrawal of consent). 2. Uncontrolled, intercurrent serious illness including but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, and/or cardiac arrhythmia likely in the judgment of the PI to interfere with clinical study requirements. 3. Psychiatric illness/condition likely in the judgment of the PI to limit compliance with clinical study requirements.